Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis. We conducted. Early-phase clinical studies of moxifloxacin. Moxifloxacin moved into clinical development for use in TB through early-phase clinical trials where the drug was given as monotherapy for a short period and confirmed that the drug was highly bactericidal, which, although less active than isoniazid, was very potent [30, 31]. Moxifloxacin is included in the WHO guidelines for the treatment of MDR TB, yet it is used off-label. It is unclear whether liability will fall on doctors if patients experience adverse events. The liability problem would extend to nurses if they began to initiate and manage MDR TB treatment. The aim of this study was to investigate the curative effect and resistance mechanisms of high-dose moxifloxacin in the short-term treatment of multidrug-resistant tuberculosis. Intuitively, as an extensive spectrum of adverse reactions to standard‐dose moxifloxacin has been reported among non‐TB patients treated for 1–2 weeks, one can reasonably predict similar, if not more frequent or severe, reactions to high‐dose moxifloxacin among TB patients treated for 9 months. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services. Moxifloxacin is a prescription drug. It comes as an oral tablet and an ophthalmic solution. It also comes as an intravenous (IV) drug, which is only given by a healthcare provider. Detailed Moxifloxacin dosage information for adults and children. Includes dosages for Sinusitis, Bronchitis, Skin or Soft Tissue Infection and more; plus renal, liver and dialysis adjustments. Moxifloxacin administration should be separated from aluminum and magnesium containing antacids, sucralfate , and multivitamins because they can lower absorption of moxifloxacin and reduce its effectiveness. They should be administered 4 hours before or 8 hours after moxifloxacin. Please note moxifloxacin is not licensed to treat tuberculosis in the UK. Despite the lack of data establishing the safety and efficacy of fluoroquinolone use in children they continue to be used to treat MDR-TB in children of all ages in clinical practice.